A fast, integrated workflow for a wide range of applications, from human whole-genome sequencing to amplicons, plasmids, and microbes.
An economical solution for sequencing RNA from FFPE tissues and other low-quality samples.
Achieve up to 15 Gb of output with improved cluster density, read length, and quality scores.
Enhanced clustering chemistry with improved signal-to-noise ratio yields even higher data quality.
Determine the best kit for your needs based on your project type, starting material, and method of interest.
From fast and flexible to ultra-high-throughput production power, find the NGS system that's right for you.
Use this beta tool to explore experimental sequencing library preparation methods compiled from the scientific literature, and find compatible kits.
The first FDA-approved NGS in vitro diagnostic for metastatic colorectal cancer for use in establishing eligibility of patients for treatment with Vectibix®.
FDA-cleared next-generation sequencing assay provides a full view of coding regions of the CFTR gene, to aid in in vitro diagnosis of cystic fibrosis.
FDA-cleared NGS assay with the largest panel of clinically relevant, functionally validated cystic fibrosis variants in a diverse population.
*For In Vitro Diagnostic Use.
Comprehensive next-generation sequencing (NGS) assay that targets DNA and RNA variants from the same FFPE sample.
Study gene expression, variants, and fusions for 1385 oncology genes, in all RNA sample types, including FFPE.
Comprehensive panels targeting disease-associated regions of the exome with high analytical sensitivity and specificity.
Assay targeting multiple variant types, including tumor mutational burden (TMB) and microsatellite instability (MSI), even from low-quality samples.
Verify instrument operation and obtain an audit-ready report to help meet regulatory requirements.
Remove both cytoplasmic and mitochondrial ribosomal RNA in a single pass.